XENOPORT'S ANNOUNCES XP19986 DATA
XenoPort has reported that a Phase IIa trial indicates XP19986 reduces symptoms of gastroesophageal reflux disease (GERD).
In the study, 35 GERD patients were given either XP19986 or placebo every four to seven days. The patients also consumed reflux-provoking meals two to six hours after dosing.
Overall, patients receiving XP19986 had a median reduction of seven fewer reflux events compared to placebo. The compound was well-tolerated with few reported adverse events.